233 related articles for article (PubMed ID: 29374809)
21. Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial.
Werlenius K; Kinhult S; Solheim TS; Magelssen H; Löfgren D; Mudaisi M; Hylin S; Bartek J; Strandéus M; Lindskog M; Rashid HB; Carstam L; Gulati S; Solheim O; Bartek J; Salvesen Ø; Jakola AS
JAMA Netw Open; 2023 Mar; 6(3):e234149. PubMed ID: 37000452
[TBL] [Abstract][Full Text] [Related]
22. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S
J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182
[TBL] [Abstract][Full Text] [Related]
23. Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks.
Sarkaria JN; Galanis E; Wu W; Dietz AB; Kaufmann TJ; Gustafson MP; Brown PD; Uhm JH; Rao RD; Doyle L; Giannini C; Jaeckle KA; Buckner JC
Clin Cancer Res; 2010 Nov; 16(22):5573-80. PubMed ID: 20921209
[TBL] [Abstract][Full Text] [Related]
24. A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes.
Azoulay M; Chang SD; Gibbs IC; Hancock SL; Pollom EL; Harsh GR; Adler JR; Harraher C; Li G; Hayden Gephart M; Nagpal S; Thomas RP; Recht LD; Jacobs LR; Modlin LA; Wynne J; Seiger K; Fujimoto D; Usoz M; von Eyben R; Choi CYH; Soltys SG
Neuro Oncol; 2020 Aug; 22(8):1182-1189. PubMed ID: 32002547
[TBL] [Abstract][Full Text] [Related]
25. Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.
Hsieh SY; Chan DT; Kam MK; Loong HH; Tsang WK; Poon DM; Ng SC; Poon WS
Hong Kong Med J; 2017 Dec; 23(6):594-8. PubMed ID: 28798282
[TBL] [Abstract][Full Text] [Related]
26. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Gan HK; Reardon DA; Lassman AB; Merrell R; van den Bent M; Butowski N; Lwin Z; Wheeler H; Fichtel L; Scott AM; Gomez EJ; Fischer J; Mandich H; Xiong H; Lee HJ; Munasinghe WP; Roberts-Rapp LA; Ansell PJ; Holen KD; Kumthekar P
Neuro Oncol; 2018 May; 20(6):838-847. PubMed ID: 29077941
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol).
Thivat E; Casile M; Moreau J; Molnar I; Dufort S; Seddik K; Le Duc G; De Beaumont O; Loeffler M; Durando X; Biau J
BMC Cancer; 2023 Apr; 23(1):344. PubMed ID: 37060055
[TBL] [Abstract][Full Text] [Related]
28. Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.
Yusuf M; Ugiliweneza B; Amsbaugh M; Boakye M; Williams B; Nelson M; Hattab EM; Woo S; Burton E
Oncology; 2018; 95(1):39-42. PubMed ID: 29694955
[TBL] [Abstract][Full Text] [Related]
29. Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.
Maraka S; Groves MD; Mammoser AG; Melguizo-Gavilanes I; Conrad CA; Tremont-Lukats IW; Loghin ME; O'Brien BJ; Puduvalli VK; Sulman EP; Hess KR; Aldape KD; Gilbert MR; de Groot JF; Alfred Yung WK; Penas-Prado M
Cancer; 2019 Feb; 125(3):424-433. PubMed ID: 30359477
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
Blakeley JO; Grossman SA; Mikkelsen T; Rosenfeld MR; Peereboom D; Nabors LB; Chi AS; Emmons G; Garcia Ribas I; Supko JG; Desideri S; Ye X
J Neurooncol; 2015 Oct; 125(1):123-31. PubMed ID: 26285766
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Zustovich F; Landi L; Lombardi G; Porta C; Galli L; Fontana A; Amoroso D; Galli C; Andreuccetti M; Falcone A; Zagonel V
Anticancer Res; 2013 Aug; 33(8):3487-94. PubMed ID: 23898124
[TBL] [Abstract][Full Text] [Related]
32. A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme.
Alonso-Basanta M; Fang P; Maity A; Hahn SM; Lustig RA; Dorsey JF
J Neurooncol; 2014 Jan; 116(2):365-372. PubMed ID: 24194293
[TBL] [Abstract][Full Text] [Related]
33. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
[TBL] [Abstract][Full Text] [Related]
34. A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study.
Lapointe S; Mason W; MacNeil M; Harlos C; Tsang R; Sederias J; Luchman HA; Weiss S; Rossiter JP; Tu D; Seymour L; Smoragiewicz M
Invest New Drugs; 2020 Aug; 38(4):1137-1144. PubMed ID: 31707687
[TBL] [Abstract][Full Text] [Related]
35. Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial.
Mallick S; Gupta S; Amariyil A; Kunhiparambath H; Laviraj MA; Sharma S; Sagiraju HKR; Julka PK; Sharma D; Rath GK
J Neurooncol; 2023 Aug; 164(1):141-146. PubMed ID: 37452916
[TBL] [Abstract][Full Text] [Related]
36. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
37. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Hainsworth JD; Ervin T; Friedman E; Priego V; Murphy PB; Clark BL; Lamar RE
Cancer; 2010 Aug; 116(15):3663-9. PubMed ID: 20564147
[TBL] [Abstract][Full Text] [Related]
38. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Patel S; DiBiase S; Meisenberg B; Flannery T; Patel A; Dhople A; Cheston S; Amin P
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):739-42. PubMed ID: 21353747
[TBL] [Abstract][Full Text] [Related]
39. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
40. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Ahluwalia MS; Reardon DA; Abad AP; Curry WT; Wong ET; Figel SA; Mechtler LL; Peereboom DM; Hutson AD; Withers HG; Liu S; Belal AN; Qiu J; Mogensen KM; Dharma SS; Dhawan A; Birkemeier MT; Casucci DM; Ciesielski MJ; Fenstermaker RA
J Clin Oncol; 2023 Mar; 41(7):1453-1465. PubMed ID: 36521103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
